Nexalis Therapeutics Limited (ASX:NX1)
Australia · Delayed Price · Currency is AUD 0.0240
0.00 (0.00%)
At close: May 6, 2026
Nexalis Therapeutics Company Description
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia.
The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler.
It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026.
Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.
Nexalis Therapeutics Limited
| Country | Australia |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Darryl Davies |
Contact Details
Address: 505 Little Collins Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 8678 4091 |
| Website | inhalerx.com.au |
Stock Details
| Ticker Symbol | NX1 |
| Exchange | Australian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | AUD |
| ISIN Number | AU0000456733 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Darryl Davies B.Sc. | Chief Executive Officer |
| Dr. Robert Jenny B.A., B.Sc., Ph.D. | Chief Scientific Officer |
| James Stephen Barrie CPA | Company Secretary |
| Greg Hammond | Chief Financial Officer |
| Srinivasa Rao Suryadevara | Executive Vice President |